Epigenetic Changes as Prognostic Markers in Patients With Early Stage Non-Small Cell Lung Cancer
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- Alliance for Clinical Trials in Oncology
- Enrollment
- 99
- Primary Endpoint
- disease specific survival
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in tissue and blood samples from patients with early-stage non-small cell lung cancer.
Detailed Description
OBJECTIVES: * Evaluate aberrant methylation patterns in tissue and serum samples from patients with early-stage non-small cell lung cancer (NSCLC) to validate the Johns Hopkins single institutional study. * Attempt to define subgroups of patients at greater risk for recurrent or metastatic disease who may benefit from more aggressive adjuvant therapeutic regimens. * Develop prognostic indicators for disease-specific and overall survival. * Define new potential molecular targets for therapy. OUTLINE: Archived tumor and intrathoracic lymph node tissue samples are analyzed for aberrant DNA methylation (p16/CDKN2A, DAP kinase, H-cadherin, APC, and RASSF1A) by methylation-specific PCR. Analyses are then compared with the preliminary data from the Johns Hopkins institutional study.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
disease specific survival
Time Frame: Up to 10 years
overall survival
Time Frame: Up to 10 years